Welcome to our dedicated page for Armata Pharmctcl news (Ticker: ARMP), a resource for investors and traders seeking the latest updates and insights on Armata Pharmctcl stock.
Armata Pharmaceuticals, Inc. (ARMP) is a clinical-stage biotechnology company pioneering bacteriophage therapeutics to combat antibiotic-resistant bacterial infections. This page serves as the definitive source for verified news and press releases related to ARMP's scientific advancements, regulatory milestones, and strategic partnerships.
Investors and researchers will find timely updates on clinical trial progress, manufacturing developments from their cGMP facility, and collaborations with government health agencies. The curated news collection covers essential updates including therapeutic candidate evaluations, intellectual property developments, and peer-reviewed research publications.
With antibiotic resistance identified as a critical global health challenge by the WHO, Armata's focus on targeted phage therapies positions its updates as particularly relevant for healthcare investors and infectious disease specialists. Regular monitoring of this resource provides insight into the company's progress toward addressing Pseudomonas aeruginosa, Staphylococcus aureus, and other priority pathogens.
Bookmark this page for streamlined access to Armata's latest scientific communications, presented with contextual clarity for both professional investors and biotechnology stakeholders.
Armata Pharmaceuticals (ARMP) has completed enrollment for its Phase 2 Tailwind study of inhaled AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic pulmonary Pseudomonas aeruginosa infection. The study, which follows the successful SWARM-P.a. trial in cystic fibrosis patients, evaluates the safety, tolerability, and efficacy of AP-PA02. Topline results are expected in the second half of 2024, with plans to commence a pivotal Phase 3 trial in 2025. The study includes two cohorts: one receiving phage-only therapy and another receiving a combination with inhaled antibiotics. The final follow-up visit is scheduled for August 7, 2024.
Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotech company, will present at the Viruses of Microbes 2024 conference in Cairns, Australia. The event occurs from July 15-19, 2024. Steven Branston, the Australia Site Head, will deliver a presentation titled 'Advancing Bacteriophage Therapy from Discovery to Clinical Trials' on July 18 at the Phage Therapy Session 2 – Clinical Application. The presentation will cover the progress in bacteriophage therapy, a promising approach for treating antibiotic-resistant bacterial infections.
Armata Pharmaceuticals, Inc. released its First Quarter 2024 financial results and corporate update. The company secured a $35 million credit agreement, continued clinical trials for phage therapeutics, and advanced its biologics manufacturing facility. Dr. Deborah Birx, CEO, highlighted progress in developing treatments for bacterial infections, with positive enrollment in clinical studies. The financials showed a grant revenue of $1.0 million, reduced research and development expenses, increased general and administrative expenses, resulting in a loss of $10.2 million from operations. Armata held $37.9 million in cash as of March 31, 2024.
FAQ
What is the current stock price of Armata Pharmctcl (ARMP)?
What is the market cap of Armata Pharmctcl (ARMP)?
